Quest Diagnostics Incorporated ($DGX) Stock Forecast: Up 6.2% Today

What is Quest Diagnostics Incorporated?

Quest Diagnostics (DGX) Market: Quest Diagnostics (DGX) had a strong bullish movement today.

Why is Quest Diagnostics Incorporated going up?

DGX stock is up 6.2% on Apr 21, 2026 16:50

• Quest Diagnostics reported impressive Q1 earnings, with net income of $251 million and adjusted earnings of $2.50 per share, surpassing analyst expectations.
• The company's revenue for the quarter reached $2.9 billion, exceeding Street forecasts, leading to a positive market sentiment.
• Quest Diagnostics provided optimistic full-year earnings guidance and revenue projections for 2026, showcasing confidence in its strategic initiatives and continued growth.
• Factors contributing to the bullish movement include strong organic expansion, increased requisition volume, and double-digit growth in Advanced Diagnostics, along with innovative solutions like Quest AD-Detect® and AI Companion.

DGX Price Chart

DGX Technical Analysis

DGX News

Quest Diagnostics: Q1 Earnings Snapshot

Quest Diagnostics Inc. reported strong first-quarter results, with net income of $251 million and adjusted earnings of $2.50 per share, exceeding analyst expectations of $2.37 per share. The company's revenue reached $2.9 billion, also surpassing Street forecasts. Quest Diagnostics provided full-year earnings guidance between $10.63 and $10.83 per share, with revenue projected to be between $11.78 billion and $11.9 billion.

https://www.kvue.com/article/syndication/associatedpress/quest-diagnostics-q1-earnings-snapshot/616-e155c99b-ab91-47a0-9b01-f09107320420

(DGX) Quest Diagnostics Expects 2026 Adjusted EPS Range $10.63 - $10.83, vs. FactSet Est of $10.63

Quest Diagnostics (DGX) announced its expectation for 2026 adjusted Earnings Per Share (EPS) to be in the range of $10.63 to $10.83, aligning with FactSet's estimate of $10.63. The company also anticipates 2026 revenue to fall between $11.78 billion and $11.90 billion, compared to FactSet's estimate of $11.76 billion. These projections follow the release of their Q1 earnings, where Quest Diagnostics reported revenue of $2.90 billion and adjusted EPS of $2.50, both surpassing FactSet estimates.

https://www.marketscreener.com/news/dgx-quest-diagnostics-expects-2026-adjusted-eps-range-10-63-10-83-vs-factset-est-of-10-63-ce7f59dbd98af424

Earnings Flash (DGX) Quest Diagnostics Incorporated Reports Q1 Revenue $2.90B, vs. FactSet Est of $2.83B

Quest Diagnostics Incorporated (DGX) reported its Q1 revenue of $2.90 billion, surpassing the FactSet estimate of $2.83 billion. The company also announced adjusted EPS of $2.50 per share, which exceeded the FactSet estimate of $2.37. Additionally, Quest Diagnostics expects its 2026 revenue to be in the range of $11.78 billion to $11.90 billion and adjusted EPS between $10.63 and $10.83.

https://www.marketscreener.com/news/earnings-flash-dgx-quest-diagnostics-incorporated-reports-q1-revenue-2-90b-vs-factset-est-of-2-ce7f59dbd98af721

Quest Diagnostics (NYSE: DGX) posts Q1 2026 growth and raises full-year outlook

Quest Diagnostics reported robust first quarter 2026 financial results, with net revenues increasing 9.2% to $2.90 billion and adjusted diluted EPS rising 13.1% to $2.50. The company attributed this growth to strong organic expansion, increased requisition volume, and double-digit growth in Advanced Diagnostics. Consequently, Quest Diagnostics has raised its full-year 2026 revenue and EPS guidance, reflecting confidence in its strategic initiatives and continued performance.

https://www.stocktitan.net/sec-filings/DGX/8-k-quest-diagnostics-inc-reports-material-event-f74b4eb96be7.html

Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

Quest Diagnostics announced strong first-quarter 2026 financial results, with revenues up 9.2% to $2.90 billion and diluted EPS increasing by 15.5% to $2.24. The company has raised its full-year 2026 revenue and EPS guidance, reflecting robust performance driven by organic growth and strategic initiatives such as Co-Lab Solutions, consumer channel expansion, and advanced diagnostic innovations including Quest AD-Detect® and AI Companion. These results highlight Quest Diagnostics' disciplined execution and focus on innovative diagnostic solutions.

https://www.prnewswire.com/news-releases/quest-diagnostics-reports-first-quarter-2026-financial-results-raises-revenue-and-eps-guidance-for-full-year-2026-302747831.html

Trending Today

MKS Instruments Inc. ($MKSI) Stock Forecast: Down 5.4% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 5.0% Today

STERIS plc (Ireland) ($STE) Stock Forecast: Up 2.5% Today

Blink Charging Co. ($BLNK) Stock Forecast: Down 5.2% Today

Sonos Inc. ($SONO) Stock Forecast: Down 5.2% Today

Tapestry Inc. ($TPR) Stock Forecast: Down 5.2% Today

Republic Services Inc. ($RSG) Stock Forecast: Up 2.3% Today

Vertex Pharmaceuticals Incorporated ($VRTX) Stock Forecast: Up 2.2% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.2% Today

Intel Corporation ($INTC) Stock Forecast: Down 5.8% Today

Quest Diagnostics Incorporated Price History

21.03.2026 - DGX Stock was up 6.2%

• Quest Diagnostics reported impressive Q1 earnings, with net income of $251 million and adjusted earnings of $2.50 per share, surpassing analyst expectations.
• The company's revenue for the quarter reached $2.9 billion, exceeding Street forecasts, leading to a positive market sentiment.
• Quest Diagnostics provided optimistic full-year earnings guidance and revenue projections for 2026, showcasing confidence in its strategic initiatives and continued growth.
• Factors contributing to the bullish movement include strong organic expansion, increased requisition volume, and double-digit growth in Advanced Diagnostics, along with innovative solutions like Quest AD-Detect® and AI Companion.

21.03.2026 - DGX Stock was up 5.9%

• Quest Diagnostics (DGX) saw a significant increase in its stock price today following the recent release of their Q1 earnings report and positive guidance for 2026.
• The company delivered strong financial results for the first quarter, surpassing revenue expectations and beating estimates for adjusted EPS, demonstrating a solid performance.
• Quest Diagnostics' optimistic forecast for 2026, with projected revenue and EPS figures higher than what analysts had predicted, boosted investor confidence and drove the upward movement in the market.
• Strong organic growth, rising requisition volume, and expansion in Advanced Diagnostics were among the key factors driving Quest Diagnostics' impressive performance and raised outlook.

10.01.2026 - DGX Stock was up 5.4%

• Quest Diagnostics (DGX) stock reached a new 52-week high and all-time high of $198.00, experiencing a strong bullish movement.
• The company's robust Q4 2025 financial results exceeded earnings and revenue estimates, contributing to the bullish trend. A positive outlook for 2026 further bolstered investor confidence.
• Despite slightly lower-than-expected FY 2026 earnings guidance, the strong quarterly performance and optimistic full-year revenue forecast overshadowed this concern.
• Investor confidence was also boosted by a dividend hike announcement and the company's history of consistent dividend payments, driving the stock price higher.

10.01.2026 - DGX Stock was up 6.8%

• Despite issuing lower-than-expected earnings guidance for FY 2026, Quest Diagnostics reported impressive Q4 results, surpassing analyst estimates for both EPS and revenue.
• The company's decision to increase its quarterly cash dividend by 7.5% and add $1 billion to its buyback program showcases its commitment to enhancing shareholder value and confidence in its financial strength.
• Quest Diagnostics' strong financial performance, optimistic revenue guidance, and strategic initiatives such as expanding collaborations and delivering clinical innovations have likely contributed to the bullish market movement, overshadowing concerns about the lower earnings guidance for the upcoming fiscal year.

10.01.2026 - DGX Stock was up 7.3%

• Quest Diagnostics reported better-than-expected Q4 2025 revenue and earnings, surpassing analyst estimates and providing an optimistic outlook for full-year 2026.
• The company's strong financial performance, including a 7.1% increase in revenue and a dividend hike, fueled investor confidence and positive market sentiment, leading to the stock's surge.
• Despite slightly lower FY 2026 earnings guidance compared to consensus estimates, the robust Q4 results and positive outlook overshadowed this concern, driving the stock to new highs.
• Quest Diagnostics' consistent dividend payments, strong revenue growth, and increased operating margins contributed to the bullish momentum, despite some warnings of the stock being slightly overvalued.

02.01.2026 - DGX Stock was down 1.0%

• The bearish movement in Quest Diagnostics (DGX) stock today could be attributed to several factors:
• The launch of a new ultrasensitive blood test for measurable residual disease (MRD) in multiple myeloma patients by Quest Diagnostics may have raised concerns about potential competition in the diagnostic testing market, impacting investor sentiment.
• The significant increase in stake by AlphaQuest LLC in Quest Diagnostics, coupled with company insiders selling off stock, might have led to uncertainty among investors about the company's future performance.
• Despite receiving a "Moderate Buy" consensus rating from analysts and positive price target revisions, the overall market sentiment towards Quest Diagnostics may have been overshadowed by the news of new product launches and insider selling activities.